Profitability
This table compares Adagio Medical and Spectral Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adagio Medical | -12,465.28% | -248.26% | -125.31% |
| Spectral Diagnostics | -832.89% | N/A | -361.73% |
Institutional and Insider Ownership
48.1% of Adagio Medical shares are held by institutional investors. 53.5% of Adagio Medical shares are held by company insiders. Comparatively, 1.5% of Spectral Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Adagio Medical and Spectral Diagnostics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adagio Medical | $266,000.00 | 99.46 | -$75.04 million | N/A | N/A |
| Spectral Diagnostics | $1.67 million | 212.57 | -$11.24 million | ($0.07) | -17.74 |
Spectral Diagnostics has higher revenue and earnings than Adagio Medical.
Risk & Volatility
Adagio Medical has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, Spectral Diagnostics has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.
Summary
Spectral Diagnostics beats Adagio Medical on 6 of the 9 factors compared between the two stocks.
About Adagio Medical
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.
About Spectral Diagnostics
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Receive News & Ratings for Adagio Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagio Medical and related companies with MarketBeat.com's FREE daily email newsletter.
